Literature DB >> 19037922

Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis.

N A Ansari1, G K Katara, V Ramesh, P Salotra.   

Abstract

Semi-quantitative RT-PCR was exploited to analyse the intralesional cytokine gene expression in 14 post-kala-azar dermal leishmaniasis (PKDL) and 10 kala-azar (KA) patients. The data provided evidence for both inflammatory and non-inflammatory responses, as reflected by elevated tumour necrosis factor (TNF)-alpha and interleukin (IL)-10 in PKDL lesions compared with normal skin tissue (n = 6). The ratio of TNF-alpha : IL-10 message was 2.66 in PKDL cases, substantially higher than in KA (1.18). Investigation of TNF-alpha receptors (TNFR1 and TNFR2) revealed a significant down-regulation of TNFR1 transcript in both PKDL and KA compared with control. In the presence of elevated levels of TNF-alpha transcript, interference with type 1 effector activity in PKDL may be due to minimal expression of the TNFR1 gene. Investigation of matrix metalloproteinases, known to be induced by TNF-alpha, and the tissue inhibitors of matrix metalloproteinases (TIMPs), provided evidence for the roles of TIMP-1 and TIMP-3 in the pathogenesis of PKDL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037922      PMCID: PMC2633225          DOI: 10.1111/j.1365-2249.2008.03761.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  A zymographic study of metalloprotease activities in extracts and extracellular secretions of Leishmania (Viannia) braziliensis strains.

Authors:  P Cuervo; L Sabóia-Vahia; F Costa Silva-Filho; O Fernandes; E Cupolillo; J B DE Jesus
Journal:  Parasitology       Date:  2005-10-03       Impact factor: 3.234

3.  Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in himachal pradesh, India.

Authors:  Nand Lal Sharma; Vikram K Mahajan; Anil Kanga; Anuradha Sood; Vishwa M Katoch; Isabel Mauricio; Chauhan D Singh; Uttam C Parwan; Vijay K Sharma; Ramesh C Sharma
Journal:  Am J Trop Med Hyg       Date:  2005-06       Impact factor: 2.345

4.  Phagocytosis of hemozoin enhances matrix metalloproteinase-9 activity and TNF-alpha production in human monocytes: role of matrix metalloproteinases in the pathogenesis of falciparum malaria.

Authors:  Mauro Prato; Giuliana Giribaldi; Manuela Polimeni; Valentina Gallo; Paolo Arese
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

5.  Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.

Authors:  Ruchi Singh; Dhiraj Kumar; Venkatesh Ramesh; Narender S Negi; Surendra Singh; Poonam Salotra
Journal:  J Infect Dis       Date:  2006-06-22       Impact factor: 5.226

6.  Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.

Authors:  Nasim A Ansari; Venkatesh Ramesh; Poonam Salotra
Journal:  J Infect Dis       Date:  2006-08-23       Impact factor: 5.226

7.  Expression of TIMP-3 gene by construction of a eukaryotic cell expression vector and its role in reduction of metastasis in a human breast cancer cell line.

Authors:  Xichun Han; Hong Zhang; Mingku Jia; Gang Han; Weidong Jiang
Journal:  Cell Mol Immunol       Date:  2004-08       Impact factor: 11.530

8.  Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar.

Authors:  Nasim Akhtar Ansari; Sumita Saluja; Poonam Salotra
Journal:  Clin Immunol       Date:  2006-03-15       Impact factor: 3.969

9.  Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis.

Authors:  Poonam Salotra; Robert C Duncan; Ruchi Singh; B V Subba Raju; Gannavaram Sreenivas; Hira L Nakhasi
Journal:  Microbes Infect       Date:  2006-01-11       Impact factor: 2.700

10.  Expression of TNF-alpha and related signaling molecules in the peripheral blood mononuclear cells of rheumatoid arthritis patients.

Authors:  Sunil Kumar Raghav; Bhawna Gupta; Charu Agrawal; Ved P Chaturvedi; Hasi R Das
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

View more
  6 in total

1.  Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL).

Authors:  Gajendra Kumar Katara; Nasim Akhtar Ansari; Avninder Singh; V Ramesh; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

Review 2.  Post kala-azar dermal leishmaniasis: an unresolved mystery.

Authors:  Debanjan Mukhopadhyay; Jane E Dalton; Paul M Kaye; Mitali Chatterjee
Journal:  Trends Parasitol       Date:  2014-01-02

Review 3.  The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Authors:  Eduard E Zijlstra
Journal:  Parasit Vectors       Date:  2016-08-23       Impact factor: 3.876

Review 4.  Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.

Authors:  Rajiv Kumar; Shashi Bhushan Chauhan; Susanna S Ng; Shyam Sundar; Christian R Engwerda
Journal:  Front Immunol       Date:  2017-11-08       Impact factor: 7.561

5.  Clinical Proteomics Profiling for Biomarker Identification Among Patients Suffering With Indian Post Kala Azar Dermal Leishmaniasis.

Authors:  Priyank Jaiswal; Manab Ghosh; Goutam Patra; Bibhuti Saha; Sumi Mukhopadhyay
Journal:  Front Cell Infect Microbiol       Date:  2020-05-27       Impact factor: 5.293

Review 6.  Precision Medicine in Control of Visceral Leishmaniasis Caused by L. donovani.

Authors:  Eduard E Zijlstra
Journal:  Front Cell Infect Microbiol       Date:  2021-11-09       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.